Influence of interferon β-1a dose frequency on PBMC cytokine secretion and biological effect markers

Journal of Neuroimmunology

Volumn 99, Issue 1, 1999, Pages 131-141

  Rothuizen, Laura E ^a   Buclin, Thierry ^a   Spertini, François ^a   Trinchard, Isabelle ^b   Munafo, Alain ^b   Buchwalder, Pierre Alexandre ^a   Ythier, Arnaud ^b   Biollaz, Jérôme ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Serono International SA   (Switzerland)

Author keywords

Clinical trials; Cytokines; Interferon beta; Leukocytes mononuclear; Multiple sclerosis

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; BETA 2 MICROGLOBULIN; BETA1A INTERFERON; BIOLOGICAL MARKER; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LYMPHOTOXIN; MITOGENIC AGENT; NEOPTERIN; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; DRUG EFFECT; HUMAN; HUMAN EXPERIMENT; IMMUNOMODULATION; MALE; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SUBCUTANEOUS DRUG ADMINISTRATION;

2',5'-OLIGOADENYLATE SYNTHETASE; ADULT; BETA 2-MICROGLOBULIN; BIOLOGICAL RESPONSE MODIFIERS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEVER; HEADACHE; HUMANS; INTERFERON TYPE II; INTERFERON-BETA; INTERLEUKIN-1; INTERLEUKIN-6; LYMPHOCYTE ACTIVATION; LYMPHOKINES; LYMPHOTOXIN-ALPHA; MALE; NEOPTERIN; RECOMBINANT PROTEINS; SAFETY; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032828063     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(99)00029-6     Document Type: Article

References (51)

1. Alam J., Goelz S., Rioux P., Scaramucci J., Jones W., McAllister A., Campion M., Roge M. Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta-1a (IFNβ-1a) products administered intramuscularly in healthy male and female volunteers. Pharm. Res. 14:1997;546-549.
2. Alam J., McAllister A., Scaramucci J., Jones W., Rogge M. Pharmacokinetics and pharmacodynamics of interferon beta-1a (IFNβ-1a) in healthy volunteers after intravenous, subcutaneous of intramuscular administration. Clin. Drug Invest. 14:1997;35-43.
3. Arnason B.G.W. Interferon beta in multiple sclerosis. Neurology. 43:1993;641-643.
4. Baker D., Butler D., Scallon B.J., O'Neill J.K., Turk J.L., Feldmann M. Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur. J. Immunol. 24:1994;2040-2048.
5. Blumhardt L.D., Paty D.W., Hugues R.A.C., Weinshenker B. Dosage effect of interferon beta-1a (Rebif) in preventing relapses and progression of disability in relapsing-remitting multiple sclerosis with EDSS>3.5. J. Neurol. 245:1998;371. Abstract.
6. Brod S.A., Nelson L.D., Khan M., Wolinsky J.S. IFN-β1b treatment of relapsing multiple sclerosis has no effect on CD3-induced inflammatory or counterregulatory anti-inflammatory cytokine secretion ex vivo after nine months. Int. J. Neurosclerot. 90:1997;135-144.
7. Chabot S., Williams G., Yong V.W. Microglial production of TNF-α is induced by activated T lymphocytes. J. Clin. Invest. 100:1997;604-612.
8. ser in healthy volunteers and its effect on serum neopterin. Pharm. Res. 10:1993;567-572.
9. Cirelli R., Herne K., Tyring S.K. Interferons - an overview of their pharmacology. Clin. Immunother. 5:1996;22-30.
10. Coclet-Ninin J., Dayer J.M., Burger D. Interferon-beta not only inhibits interleukin-1β and tumor necrosis factor-α but stimulates interleukin-1 blood mononuclear cells. Eur. Cytokine Netw. 8:1997;345-349.
11. Coclet-Ninin J., Dayer J.M., Burger D. Interferon-β not only inhibits interleukin-β and tumor necrosis factor-α but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells. Eur. Cytokine Netw. 8:1997;345-349.
12. Dettke M., Scheidt P., Prange H., Kirchner H. Correlation between interferon production and clinical disease activity in patients with multiple sclerosis. J. Clin. Immunol. 17:1997;293-300.
13. Fierlbeck G., Ulmer A., Schreiner T., Stroebel W., Schiebel U., Brzoska J. Pharmacodynamics of recombinant IFN-β during long-term treatment of malignant melanoma. J. Interferon Cytokine Res. 16:1996;777-781.
14. Gayo A., Mozo L., Suarez A., Tuñon A., Lahoz C., Gutierrez C. Glucocorticoids increase IL-10 expression in multiple sclerosis patients with acute relapse. J. Neuroimmunol. 85:1998;122-130.
15. + B cells in active multiple sclerosis and reversal by interferon β-1b therapy. J. Clin. Invest. 99:1997;2664-2671.
16. Hartung H.P., Archelos J.J., Zielasek J., Gold R., Koltzenburg M., Reiners K.H., Toyka K.V. Circulating adhesion molecules and inflammatory mediators in demyelination: a review. Neurology. 45:1995;S22-S32.
17. Hohlfeld R., Meinl H., Weber F., Zipp F., Schmidt S., Sotgiu S., Goebels N., Voltz R., Spuler S., Iglesias A., Wekerle H. The role of autoimmune T lymphocytes in the pathogenesis of multiple sclerosis. Neurology. 45:1995;S33-S37.
18. Huhn R.D., Radwanski E., Gallo J., Affrime M.B., Sabo R., Gonyo G., Monge A., Cutler D.L. Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteers. Clin. Pharmacol. Ther. 62:1997;171-180.
19. Jacobs L.D., Cookfair D.L., Rudick R., Herndon R.M., Richert J.R., Salazar A.M., Fischer J.S., Goodkin D.E., Granger K.V., Simon J.H., Alam J.J., Bartoszak D.M., Bourdette D.N., Braiman J., Brownscheidle C.M., Coats M.E., Cohan S.L., Dougherty D.S., Kinkel R.P., Mass M.K., Munschauer F.E., Priore R.L., Pullicino P.M., Scherokman B.J., Weinstock-Guttman B., Witham R.H. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann. Neurol. 39:1996;285-294.
20. Khan O.A., Xia Q., Bever C.T., Johnson K.P., Panitch H.S., Dhib-Jalbut S.S. Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration. Neurology. 46:1996;1639-1643.
21. Knobler R.L., Greenstein J.L., Johnson K.P., Lublin F.D., Panitch H.S., Conway K., Grant-Gorsen S.V., Muldoon J., Marcus S.G., Wallenberg J.C. Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. J. Interferon Res. 13:1993;333-340.
22. Lehtonen A., Matikainen S., Julkunen I. Interferons up-regulate STAT1, STAT2, and IRF family transcription factor gene expression in human peripheral blood mononuclear cells and macrophages1. J. Immunol. 159:1998;794-803.
23. Liberati A.M., Garofani P., De Angelis V., Di Clemente F., Horisberger M., Cecchini M., Betti A.R., Palmisano L., Astolfi S., Nastari A., Villa A., Arzano S. Double-blind randomized phase I study on the clinical tolerance and pharmacodynamics of natural and recombinant Interferon-β given intravenously. J. Interferon Res. 14:1994;61-69.
24. Martinez-Moczygemba M., Gutch M.G., French D.L., Reich N.C. Distinct STAT structure promotes interaction of STAT2 with the P48 subunit of the interferon-α-stimulated transcription factor ISGF3*. J. Biol. Chem. 272:1997;20070-20076.
25. McRae B.L., Semnani R.T., Hayes M.P., Van Seventer G.A. Type I IFNs inhibit human dendritic cell IL-12 production and Th1 cell development1. J. Immunol. 160:1998;4298-4304.
26. Munafo A., Trinchard-Lugan I., Nguyen T.X.Q., Buraglio M. Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular subcutaneous administration. Eur. J. Neurol. 5:1998;187-193.
27. Noronha A., Toscas A., Jensen M.A. Interferon β decreases T cell activation and interferon gamma production in multiple sclerosis. J. Neuroimmunol. 46:1993;145-154.
28. Olsson T. Cytokine-producing cells in experimental autoimmune encephalomyelitis and multiple sclerosis. Neurology. 45:1995;S11-S15.
29. Pestka S. The interferon receptors. Semin. Oncol. 24:1997;S9-S18.
30. Porrini A.M., Gambi D., Rder A.T. Interferon effects on interleukin-10 secretion mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients. J. Neuroimmunol. 61:1995;27-34.
31. Pozzilli C., Bastianello S., Koudriavtseva T., Gasperini C., Bozzao A., Millefiorini E., Galgani S., Buttinelli C., Perciaccante G., Piazza G., Bozzao L., Fieschi C. Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 61:1996;251-258.
32. Rep M.H.G., Hintzen R.Q., Polman C.H., Van Lier R.A.W. Recombinant interferon-β blocks proliferation but enhances interleukin-10 secretion by activated human T-cells. J. Neuroimmunol. 67:1996;111-118.
33. Rosztoczy I., Content J. The effects of various cytokines on interleukin-6 and interferon-α synthesis in human peripheral blood mononuclear cells. J. Interferon Res. 10:1990;637-645.
34. Rudick R.A., Cohen J.A., Weinstock-Guttman B., Kinkel R.P., Ransohoff R.M. Management of multiple sclerosis. New Engl. J. Med. 337:1997;1604-1611.
35. Rudick R.A., Goodkin D.E., Jacobs L.D., Cookfair D.L., Herndon R.M., Richert J.R., Salazar A.M., Fischer J.S., Granger C.V., Simon J.H., Alam J.J., Simonian N.A., Campion M.K., Bartoszak D.M., Bourdette D.N., Braiman J., Brownscheidle C.M., Coats M.E., Cohan S.L., Dougherty D.S., Kinkel R.P., Mass M.K., Munschauer F.E., Priore M.L., Pullicino P.M., Scherokman B.J., Weistock-Guttman B., Whitham R.H. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. Neurology. 49:1997;358-363.
36. Salmon P., Le Cotonnec J.Y., Galazka A., Abdul-Ahad A., Darragh A. Pharmacokinetics and pharmacodynamics of recombinant human interferon-β in healthy male volunteers. J. Interferon Res. 16:1996;759-764.
37. Selmaj K., Raine C.S., Cannella B., Brosnan C.F. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J. Clin. Invest. 87:1991;949-954.
38. Sharief M.K., Thompson E.J. In vivo relationship of tumor necrosis factor-α to blood-brain barrier damage in patients with active multiple sclerosis. J. Neuroimmunol. 38:1992;27-34.
39. Shindo M., Okuno T., Matsumoto M., Takeda M., Takino T., Sokawa J., Iwata A., Sokawa Y. Serum 2′,5′-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis B. Hepatology. 8:1988;366-370.
40. Spertini F., Chatila T., Geha R.S. Signals delivered via MHC Class II molecules synergize with signals delivered via TCR/CD3 to cause proliferation and cytokine gene expression in T cells. J. Immunol. 149:1992;65-70.
41. Stewart V.C., Land J.M., Clark J.B., Heales S.J.R. Pretreatment of astrocytes with interferon-α/β prevents neuronal mitochondrial respiratory chain damage. J. Neurochem. 70:1998;432-434.
42. Stinissen, P., Raus, J., Zhang, J., 1997. Autoimmune pathogenesis of multiple sclerosis: role of autoreactive T lymphocytes and new immunotherapeutic strategies. Crit. Rev. Immunol., 33-75.
43. The IFNB Multiple Sclerosis Study Group Interferon-beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology. 43:1993;655-661.
44. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group Interferon beta-1b in the treatment of multiple sclerosis. Neurology. 45:1995;1277-1285.
45. The PRISMS Study Group Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 352:1998;1498-1504.
46. Vial T., Descotes J. Clinical toxicity of the interferons. Drug Safety. 10:1994;115-150.
47. Weinstock-Guttman B., Rudick R.A. Prescribing recommendations for interferon-beta in multiple sclerosis. CNS Drugs. 8:1997;102-112.
48. Williams G.J., Witt P.L. Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and Avonex. J. Interferon Cytokine Res. 18:1998;967-975.
49. Witt P.L., Storer B.E., Bryan G.T., Brown R.R., Flashner M., Larocca A.T., Colby C.B., Borden E.C. Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-β J. Immunother. 13:1993;191-200.
50. Witter F., Barouki F., Griffin D., Nadler P., Woods A., Wood D., Lietman P. Biologic response (antiviral) to recombinant human interferon alpha 2a as a function of dose and route of administration in healthy volunteers. Clin. Pharmacol. Ther. 42:1987;567-575.
51. Yamazaki S., Kuramoto K., Matsuo E., Hosoi K., Hara M., Shimizu H. Highly sensitive enzyme immunoassay of human interferon-β1. J. Immunoassay. 10:1989;57-73.